Mulmit

Allogene Therapeutics, Inc.Allogene Therapeutics, Inc.

ALLO Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-310-209,315,000-190,886,000-0.87
2024-12-3122,000-273,199,000-257,590,000-1.32
2023-12-3195,000-327,737,000-327,265,000-2.09
2022-12-31156,000-335,536,000-340,414,000-2.38
2021-12-31114,089,000-180,192,000-182,051,000-1.34

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-21Douglas Earl MartinSVP, General Counsel29,697
2026-07-01Roberts ZacharyPresident and CEO134,530
2026-07-01Roberts ZacharyPresident and CEO476,190
2026-06-18Barrett Elizabeth A.95,400
2026-06-18MESSEMER DEBORAH M.95,400
2026-06-18Mayo Stephen144,400
2026-06-18WITTE OWEN N.95,400
2026-06-18Humer Franz B95,400
2026-06-18Kazam Joshua A47,700
2026-06-18Kazam Joshua A47,700
2026-06-18Kazam Joshua A95,400
2026-06-18SATO VICKI L95,400

8-K events

FiledItems
2026-09-02Officer or director change
2026-08-12Results of operations · Financial statements and exhibits
2026-06-22Submission of matters to a vote · Other events
2026-05-28Officer or director change
2026-05-13Entry into a material agreement · Termination of a material agreement · Results of operations · Financial statements and exhibits
2026-04-15Other events · Financial statements and exhibits
2026-04-13Other events
2026-04-13Other events
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Biological Products, (No Diagnostic Substances) — 같은 업종, 그리고 규모가 비슷한 기업Biological Products, (No Diagnostic Substances) — and other companies of a similar size

SEC가 같은 업종(Biological Products, (No Diagnostic Substances))으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Biological Products, (No Diagnostic Substances)) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.